[Note to Affiliate: HCP-delivered patient materials and their inclusion herein are subject to local codes and regulations.]
Watch this Introduction to RINVOQ video, for patients prescribed RINVOQ. This video is supplementary to the Patient Information Leaflet.
Hear a rheumatologist and a dermatologist discuss their experiences using RINVOQ with their patients.
[AFFILIATES TO INSERT CONTENT AS APPLICABLE PER LOCAL CODES AND REGULATIONS AND MRLO APPROVALS]
This guide has been designed to help your patients who have been prescribed RINVOQ, to navigate their treatment journey step-by-step.
Printed Materials
For patients who prefer not to receive information digitally, all items are available as hard copy materials.
[AFFILIATES TO INSERT CONTENT ONCE AVAILABLE, AS APPLICABLE PER LOCAL REGULATIONS AND MRLO APPROVALS]
[AFFILIATES TO INSERT CONTENT ONCE AVAILABLE, AS APPLICABLE PER LOCAL REGULATIONS AND MRLO APPROVALS]
[AFFILIATES TO INSERT CONTENT ONCE AVAILABLE, AS APPLICABLE PER LOCAL REGULATIONS AND MRLO APPROVALS]
[AFFILIATES TO INSERT CONTENT ONCE AVAILABLE, AS APPLICABLE PER LOCAL REGULATIONS AND MRLO APPROVALS]
To receive printed versions of any of these materials for your patients, submit your details on the Contact Us page.
[AFFILIATES TO INSERT CONTENT ONCE AVAILABLE, AS APPLICABLE PER LOCAL REGULATIONS AND MRLO APPROVALS]
Read more about the RINVOQ Phase 3 clinical trial program for ulcerative colitis here
[Affiliate to insert PubMed link to Danese manuscript, if applicable]
RINVOQ is an oral, once-daily, selective and reversible JAK inhibitor now approved for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were tolerant to either conventional therapy or a biologic agent.1
RINVOQ can be taken at any time of the day, with or without food.1
A Phase 3 clinical trial program involving 3 studies: 2 replicate induction studies and 1 maintenance study evaluated RINVOQ 45 mg vs placebo for induction, and RINVOQ 15 mg and 30 mg vs placebo for maintenance treatment.1,2
Learn more about RINVOQ in our quick introductory video.
JAK: Janus kinase; UC: ulcerative colitis.
REFERENCES
- RINVOQ Summary of Product Characteristics.
- Danese S, Vermeire S, Zhou W, et al. Lancet. 2022;399(10341):2113–2128.